It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Predicting how Leishmania will respond to control efforts requires an understanding of their transmission strategy. Using real-time quantitative PCR to quantify infectious metacyclic and non-metacyclic forms in mouse skin from single sandfly bites we show that most transmissions were highly enriched for infectious parasites. However, a quarter of sandflies were capable of transmitting high doses containing more non-infectious promastigotes from the vector’s midgut. Mouse infections replicating “high” to “low” quality, low-dose transmissions confirmed clear differences in the pathology of the infection and their onward transmissibility back to sandflies. Borrowing methods originally developed to account for exposure heterogeneity among hosts, we show how these high-dose, low-quality transmitters act as super-spreading vectors, capable of inflating Leishmania transmission potential by as much as six-fold. These results highlight the hidden potential of transmission of mixed Leishmania promastigote stages on disease prevalence and the role of dose heterogeneity as an underlying strategy for efficient transmission.
Emilie, Giraud et al. show that high-dose, low-quality transmitters act as super-spreading parasite vectors, inflate Leishmania transmission potential by six-fold. This study highlights the role of Leishmania promastigote dose heterogeneity as an underlying strategy for efficient parasite transmission.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 London School of Hygiene and Tropical Medicine, Department of Immunology and Infection, Faculty of Infectious Tropical Diseases, London, UK (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X); Institut Pasteur, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535)
2 London School of Hygiene and Tropical Medicine, Department of Disease Control, Faculty of Infectious Tropical Diseases, London, UK (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X)